Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug
Clinical trial NCT05203679 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05203679
- Sponsor
- Shanghai Xinzhi BioMed Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-30
- Primary completion
- 2024-04-16
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.